Q-omics provides the consensus-scored KRT75 profile across patient tissues and cancer cell-line models. KRT75 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KRT75 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, KRT75 protein abundance shows 12,414 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRC, COAD, and HNSC as cancer lineages where KRT75 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT75 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT75 survival associations across molecular data types. KRT75 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT75 RNA expression–survival associations across cancer types. High KRT75 expression shows unfavorable associations in KIRC, KICH, LGG, SKCM, MESO and LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KRT75 RNA expression.
This table summarizes KRT75 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 3. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for KRT75. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT75 shows higher tumor expression in COAD, LUSC, HNSC, UCEC, LUAD and BRCA. The COAD box plot shows higher KRT75 RNA expression in tumor versus normal tissue (log2 FC = +1.164, t-test p < 0.001).
This table shows molecular features associated with KRT75 in patient tissues and cancer cell lines. In patient samples, KRT75 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, KRT75 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
